FDA Approves OXCARBAZEPINE — EPIC PHARMA, LLC

On November 30, 2022, **Epic Pharma, LLC** announced the approval of its Abbreviated New Drug Application (ANDA) 215332 for OXCARBAZEPINE, ensuring continued market access for the anticonvulsant blockbuster drug. This approval is expected to positively impact the company's revenue streams by maintaining a competitive edge against generic formulations, preserving Epic Pharma's presence in the neurology segment during the patent expiry period.